Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function

Area of Science:

• Bone Biology
• Cellular and Molecular Medicine
• Endocrinology

Background:

• Osteoprotegerin (OPG) is a key inhibitor of osteoclast differentiation and function.
• OPG deficiency in mice results in severe osteoporosis due to increased osteoclastic bone resorption.
• The precise role of OPG in osteoclast differentiation requires further investigation.

Purpose of the Study:

• To examine the potential roles of OPG in osteoclast differentiation.
• To investigate the mechanism by which OPG regulates osteoclast formation.
• To clarify the function of RANKL expressed by osteoblasts.

Main Methods:

• Utilized a mouse coculture system with calvarial osteoblasts and bone marrow cells from OPG-deficient mice.
• Assessed osteoclast formation in the absence and presence of bone-resorbing factors.
• Analyzed RANKL messenger RNA expression and bone-resorbing activity in organ cultures.

Main Results:

• OPG-deficient osteoblasts strongly supported spontaneous osteoclast formation.
• Addition of OPG completely inhibited spontaneous osteoclast formation in OPG-deficient cocultures.
• RANKL expressed by osteoblasts acts as a membrane-associated factor, essential for osteoclast differentiation.

Conclusions:

• Osteoprotegerin (OPG) produced by osteoblasts/stromal cells is a critical physiological regulator of osteoclast differentiation and function.
• Receptor activator of nuclear factor-kappaB ligand (RANKL) expressed by osteoblasts functions as a membrane-associated form.
• These findings underscore the importance of the OPG/RANKL system in bone homeostasis.